With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
June 16, 2017. This week’s JCO pub looks at 1206 patients with intermediate risk prostate cancer randomized to receive 78 Gy / 39 (8 wks) versus 60 Gy / 20 (4 wks) of definitive radiation without androgen deprivation therapy (ADT). With a median follow-up of 6 years, the primary endpoint of freedom from biochemical failure was 85% in both arms, meeting a predefined non-inferiority threshold without the expense of additional late GU and GI toxicity. This supports last year’s JCO pub establishing non-inferiority of 70 Gy / 28 for low risk prostate cancer. And on the other end of the disease spectrum, final results of a phase 3 trial of hypofractionation in high risk prostate cancer (though negative in terms of its primary endpoint of improving late toxicity) interestingly showed a trend towards improved cancer-specific survival at 10-years with 62 Gy / 20 (95%) versus 80 Gy / 40 (88%, p=0.066). Looks like curing prostate cancer is getting shorter and sweeter every day.